Publications

Evaluation Study
Journal Article Research Support, N.I.H., Extramural
Ppublish 155 citations
Open access — free full text available
Open access
Electronic publication date
April 21, 2020

View on Pubmed.gov 30891595 | View on doi.org 10.1093/annonc/... (full text)

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.

Search for publications in this journal Ann Oncol - 30(4):597-603

Abstract

BACKGROUND

Noninvasive genotyping using plasma cell-free DNA (cfDNA) has the potential to obviate the need for some invasive biopsies in cancer patients while also elucidating disease heterogeneity. We sought to develop an ultra-deep plasma next-generation sequencing (NGS) assay for patients with non-small-cell lung cancers (NSCLC) that could detect targetable oncogenic drivers and resistance mutations in patients where tissue biopsy failed to identify an actionable alteration.

PATIENTS AND METHODS

Plasma was prospectively collected from patients with advanced, progressive NSCLC. We carried out ultra-deep NGS using cfDNA extracted from plasma and matched white blood cells using a hybrid capture panel covering 37 lung cancer-related genes sequenced to 50 000× raw target coverage filtering somatic mutations attributable to clonal hematopoiesis. Clinical sensitivity and specificity for plasma detection of known oncogenic drivers were calculated and compared with tissue genotyping results. Orthogonal ddPCR validation was carried out in a subset of cases.

RESULTS

In 127 assessable patients, plasma NGS detected driver mutations with variant allele fractions ranging from 0.14% to 52%. Plasma ddPCR for EGFR or KRAS mutations revealed findings nearly identical to those of plasma NGS in 21 of 22 patients, with high concordance of variant allele fraction (r = 0.98). Blinded to tissue genotype, plasma NGS sensitivity for de novo plasma detection of known oncogenic drivers was 75% (68/91). Specificity of plasma NGS in those who were driver-negative by tissue NGS was 100% (19/19). In 17 patients with tumor tissue deemed insufficient for genotyping, plasma NGS identified four KRAS mutations. In 23 EGFR mutant cases with acquired resistance to targeted therapy, plasma NGS detected potential resistance mechanisms, including EGFR T790M and C797S mutations and ERBB2 amplification.

CONCLUSIONS

Ultra-deep plasma NGS with clonal hematopoiesis filtering resulted in de novo detection of targetable oncogenic drivers and resistance mechanisms in patients with NSCLC, including when tissue biopsy was inadequate for genotyping.

References

J Thorac Oncol. 2015 May;10(5):768-777

J Natl Cancer Inst. 2019 Jun 1;111(6):575-583

Nat Commun. 2017 Nov 6;8(1):1324

JAMA Oncol. 2016 Aug 1;2(8):1014-22

Cited by 155 citations (total)

Journal Article Research Support, Non-U.S. Gov't

Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial.

Electronic publication date October 28, 2020

Search for publications in this journal Mol Oncol

Atocha Romero [...] Mariano Provencio et al.

Several platforms for noninvasive EGFR testing are currently used in the clinical setting with sensitivities ranging from 30% to 100%....

Journal Article

Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients.

Electronic publication date April 9, 2020

Search for publications in this journal PLoS One

Eirini Papadopoulou [...] George Nasioulas et al.

BACKGROUND

Analysis of circulating tumor nucleic acids in plasma of Non-Small Cell Lung Cancer (NSCLC) patients is the most widespread and...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances

Copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.